Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).
Status:
Completed
Trial end date:
2020-02-13
Target enrollment:
Participant gender:
Summary
Purpose:
The overall hypothesis of the study is that the benefits attained in the EMPA-OUTCOME were,
at least in part, mediated by a glucose-independent mechanism. Thus, to demonstrate the
existence of the postulated non-glucose dependent effects, the researchers will investigate
the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical
therapy in heart failure patients with reduced ejection fraction without diabetes.